Literature DB >> 23657863

Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients.

Fabian P Siegel1, Jan Tauscher, Petro E Petrides.   

Abstract

Aquagenic pruritus (AP) is a symptom typical for polycythemia vera, but very little is known about its exact frequency, characteristics, influence on quality of life, and proper treatment. Therefore, we investigated these aspects in a large cohort of German patients with polycythemia vera using a patient directed questionnaire. Our analysis revealed that 301 of 441 analyzed patients suffered from AP. In 64.8%, AP occurred on average 2.9 years prior to diagnosis of polycythemia vera. Only in 15.4% did this lead to a hematological investigation. AP occurs primarily on the trunk and proximal parts of the extremities. Most patients complain about itching (71.8%), the remainder about tickling, stinging, or burning sensations. Forty-four patients (14.6%) classified the pruritus as "unbearable." Patients with AP reported reduced global health status and higher fatigue, pain, and dyspnea. Only 24% of patients received pruritus specific treatment for pruritus consisting mostly of histamine antagonists, which ameliorated symptoms in about half of the patients. In 5.6% of patients, polycythemia vera directed therapy (phlebotomy/cytoreduction) resolved the symptoms. In summary, AP is a serious symptom in patients with polycythemia vera, which until recently was difficult to treat. The advent of the novel JAK2 inhibitors, however, may open new ways for therapy.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23657863     DOI: 10.1002/ajh.23474

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  21 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

2.  Optimized and Personalized Phlebotomy Schedules for Patients Suffering From Polycythemia Vera.

Authors:  Patrick Lilienthal; Manuel Tetschke; Enrico Schalk; Thomas Fischer; Sebastian Sager
Journal:  Front Physiol       Date:  2020-04-17       Impact factor: 4.566

Review 3.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 4.  Austrian recommendations for the management of polycythemia vera.

Authors:  Sonja Burgstaller; Veronika Buxhofer-Ausch; Thamer Sliwa; Christine Beham-Schmid; Günther Gastl; Klaus Geissler; Thomas Melchardt; Maria Krauth; Peter Krippl; Andreas Petzer; Holger Rumpold; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2018-07-19       Impact factor: 1.704

Review 5.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 6.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

Review 7.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

Review 8.  Itch: Epidemiology, clinical presentation, and diagnostic workup.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2021-08-21       Impact factor: 11.527

9.  Burning feet in polycythemia vera - peripheral sensorimotor axonal neuropathy with erythromelalgia.

Authors:  Uwe Wollina
Journal:  Int J Gen Med       Date:  2015-02-02

Review 10.  Non-dermatological Challenges of Chronic Itch.

Authors:  Andreas E Kremer; Thomas Mettang; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.